Premium
Controlled clinical trial of injection sclerotherapy for active variceal bleeding
Author(s) -
Westaby David,
Hayes Peter C.,
Gimson Alexander E. S.,
Polson Rex J.,
Williams Roger
Publication year - 1989
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840090219
Subject(s) - medicine , sclerotherapy , vasopressin , anesthesia , surgery , varices , endoscopy , bleed , varix , gastroenterology , cirrhosis
In a prospective, randomized clinical trial, immediate injection sclerotherapy was compared with treatment by a combined infusion of vasopressin (0.4 unit per min) and nitroglycerin (40 to 400 μg per min) in 50 consecutive patients with 64 episodes of endoscopy‐proven active variceal hemorrhage. Control of bleeding was assessed over a 12‐hr period following entry into the trial. Patients in the vasopressin + nitroglycerin group were then treated by sclerotherapy, as were those in the sclerotherapy group who continued to bleed. At 12 hr, bleeding was controlled in 29 (88%) of the 33 episodes treated by sclerotherapy compared with 20 (65%) of 3 episodes treated by vasopressin + nitroglycerin (p<0.05). Recurrence of variceal bleeding occurred at the same frequency (31%). Although admission mortality was less in those initially treated by sclerotherapy compared to those managed by vasopressin + nitroglycerin, this did not reach statistical significance (27 and 39%, respectively, p>0.20). Sclerotherapy carried out as the first treatment of the active variceal hemorrhage proved both safe and effective, even in the presence of major hemorrhage, and as compared to combined vasopressin and nitroglycerin it proved superior.